Company Overview

Saroja Pharma Industries India Ltd was originally incorporated as a Private Limited company on January 14, 2019, under the name "Saroja Pharma Industries India Private Limited". It was later converted into a Public Limited Company, and its name was changed to "Saroja Pharma Industries India Limited" via a fresh Certificate of Incorporation dated April 18, 2023. Founded in 2019 by Mr. Biju Gopinathan Nair and Mr. Manish Dasharath Kamble, Saroja Pharma aims to be a globally integrated and highly regarded pharmaceutical and healthcare company.

Saroja Pharma Industries India Limited is an India-based pharmaceutical and healthcare company focused on trading in Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, chemicals, and solvents used for pharmaceutical products for both human and veterinary medicine. The company operates across three primary product categories, engaging in comprehensive pharmaceutical trading activities that serve both domestic and international markets.

Core Business Segments and Products

The Company deals in three main product categories: Chemical, Pharma Intermediary, and API.

- Chemical Products include Liquid Bromine, Ethyl Acetate, Thionyl Chloride, Para Nitro Phenol, Toluene N.G, and Benzyl Chloride.

- API Products include Bromhexine HCL BP Grade, Triclabendazole, Fenbendazole BP Vet, Nitroxynil BP Vet, Oxfendazole BP Vet, Albendazole USP, Rafoxanide BP Vet, and Febantel EP, among others.

The company is also engaged in the import and export of specialty chemicals, supplying them to various users. Its specialty chemicals and intermediates have wide applications in sectors like pharma, agro, and chemicals for humans and veterinarians. Saroja Pharma has strategically positioned itself in the pharmaceutical supply chain, catering to manufacturers requiring high-quality raw materials and intermediates for drug production.

Presently, the Company trades in Active Pharmaceuticals Ingredients (API), Pharma Intermediates, Specialty Chemicals, Intermediates for Pharma trading, and Solvents used for pharmaceutical products in human and veterinary medicine. Product demand from clients is manufactured as per their specifications by suppliers, initially in sample sizes. Once clients test and approve, the order is finalized, and the specified product is manufactured for the required quantity and dispatched via appropriate transport modes within India or abroad.

Market Position and Trading Information

The stock symbol for Saroja Pharma Industries India Ltd is SAROJA. The market capitalization of Saroja Pharma Industries India Ltd (SAROJA) is ₹15.28 Cr as of 25th April 2025. The company trades on both NSE and BSE exchanges, providing accessibility to retail and institutional investors.

The 52-week high for Saroja Pharma Industries India Ltd (SAROJA) is ₹70.75, and the 52-week low is ₹33.10. This trading range reflects the stock's volatility and market dynamics over the past year, indicating significant price movements that investors should consider.

Financial Performance and Key Metrics

The company has demonstrated operational performance in the pharmaceutical trading sector, although there are areas for improvement. Saroja Pharma Industries India Ltd has an operating revenue of ₹130.71 Cr on a trailing 12-month basis.

Key Profitability Metrics and Trends:

- Annual revenue de-growth of -19% needs improvement.

- Pre-tax margin of 3% needs improvement.

- Return on Equity (ROE) of 5% is fair but can be improved.

From the IPO prospectus data, Saroja Pharma Industries India IPO posted revenues of ₹50.35 Cr and Profit After Tax (PAT) of ₹1.06 Cr in FY25 on an annualized basis.

Key Financial Highlights (FY25 Annualized):

- Revenue: ₹50.35 Cr

- EBITDA: ₹2.88 Cr

- PAT: ₹1.06 Cr

- Net Worth: ₹5.09 Cr

The current PE ratio of Saroja Pharma Industries India Ltd (SAROJA) is 17.43. The current PB ratio is 1.04. The company has a reasonable debt-to-equity ratio of 18%, signaling a healthy balance sheet.

Shareholding Pattern and Corporate Governance

As of March 2025, company promoters held 73.02% of the stake in SAROJA PHARMA INDUSTRIES INDIA LTD., with no shares pledged. This high promoter holding indicates strong management confidence in the company's future prospects and contributes to the stability of the shareholding structure.

Recent Corporate Developments:

- Appointments: Manish Kamble appointed as CFO; P.G. Kanvinde & Associates appointed as internal auditor for FY 2025-26.

- Resignation: Independent Director Abhishek Agrawal resigned effective May 5, 2025, citing personal reasons.

Growth Strategy and Future Outlook

Prior to its recent developments, the Company witnessed a substantial expansion in its clientele base over the past two years. This growth has propelled the Company to venture into the manufacturing of API Pharma products, aiming to make cost-effective contributions to human and veterinary medicine. This strategic shift from pure trading to manufacturing indicates the company's ambition to move up the value chain and potentially improve profit margins.

The Company is planning a Public Issue of 10,84,800 Equity Shares aggregating to ₹9.11 Crores through a Fresh Issue. These capital-raising initiatives demonstrate the management's commitment to funding growth plans and expanding operational capabilities.

The pharmaceutical industry's growing demand for quality APIs and intermediates, particularly in the post-pandemic environment, positions Saroja Pharma favorably for potential expansion. The company's established relationships with clients and suppliers, combined with its expertise in pharmaceutical trading, provide a foundation for sustained growth in the evolving healthcare market.